The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size. Issue 8 (13th August 2020)

• Record Type: Journal Article
• Authors: Boertien, Tessel M; Drent, Madeleine L; Booij, Jan; Majoie, Charles B L M; Stokkel, Marcel P M; Hoogmoed, Jantien; Pereira, Alberto; Biermasz, Nienke R; Simsek, Suat; Groote Veldman, Ronald; Tanck, Michael W T; Fliers, Eric; Bisschop, Peter H
• Is Part Of: BMJ open. Volume 10:Issue 8(2020)
• Publication Date: 2020-08-13
• Subjects: pituitary disorders -- endocrine tumours -- nuclear radiology -- clinical trials; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-038250
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: At present, there is no approved medical treatment option for patients with non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression. In vivo somatostatin receptor imaging using 68 Ga-DOTATATE PET (PET, positron emission tomography) could help in preselecting patients potentially responsive to treatment. Our aim is to investigate the effect of the somatostatin analogue lanreotide as compared with placebo on tumour size in patients with a 68 Ga-DOTATATE PET-positive non-functioning pituitary macroadenoma (NFMA). Methods and analysis: The GALANT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients with a suprasellar extending NFMA. Included patients undergo a 68 Ga-DOTATATE PET/CT of the head and tracer uptake is assessed after coregistration with pituitary MRI. Forty-four patients with a 68 Ga-DOTATATE PET-positive NFMA are randomised in a 1:1 ratio between lanreotide 120 mg or placebo, both administered as subcutaneous injections every 28 days for 72 weeks. The primary outcome is the change in cranio-caudal tumour diameter on pituitary MRI after treatment. Secondary outcomes are change in tumour volume, time to tumour progression, change in quality of life and number of adverse events. Final results are expected in the second half of 2021. Ethics and dissemination: The study protocol has been approved by the Medical Research Ethics Committee of the Academic Medical Centre (AMC) of the Amsterdam University Medical Centres and by the Dutch competent authority. It is an investigator-initiated study with financial support by Ipsen Farmaceutica BV. The AMC, as sponsor, remains owner of all data. Results will be submitted for publication in a peer-reviewed journal. Trial registration number: NL5136 (Netherlands Trial Register); pre-recruitment.